- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00544687
Phase I Study of Topical CRx-191 in Normal Healthy Volunteers
November 14, 2007 updated by: Zalicus
A Phase I, Single-Center, Randomized, Vehicle and Active-Controlled Study to Assess and Compare the Atrophy-Causing Potential of Topical CRx-191 Formulations in Healthy Volunteers
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy.
CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor- alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of psoriasis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamburg, Germany
- Bioskin GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must voluntarily give written informed consent
- Subject must be at least 18 years of age
- Subject must have healthy skin on which reddening can be easily recognized in the area of the test fields
- The physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study
- Sexually active females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen; systemic contraceptive (combined oral contraceptive, implant, injection), or safe intrauterine device (IUD)
- Written informed consent obtained
Exclusion Criteria:
- Acne, suntan, eczema, hyper- or hypopigmentation, or tattoos in the test fields
- Dark skinned persons whose skin color prevents ready assessment of skin reactions
- Cardiac disease including recent myocardial infarction, any degree of heart block or other cardiac arrhythmias and valvular heart disease
- Mania
- Narrow angle glaucoma
- Hyperthyroidism by medical history, TSH < LLN, or receiving thyroid medication
- Severe liver disease (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) laboratory values that exceed 1.5x ULN)
- Inflammatory dermatoses (e.g. atopic dermatitis, psoriasis), bacterial, viral, or fungal skin infections; facial rosacea
- Active varicella, tuberculosis, syphilis or post-vaccine reactions
- Autoimmune disease (e.g., lupus erythematosis)
- Known allergic reactions or hypersensitivity to any of the components of the study preparations
- Allergy to adhesives on the patches used for occlusion in this study
- UV therapy in the four weeks before the study
- History of malignancy (except for treated or excised basal cell carcinoma)
- Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
- History of drug or alcohol abuse (as defined by the Investigator)
- Symptoms of a clinically significant illness in the four weeks before the study that may influence the outcome of the study
- Positive for human immunodeficiency virus (HIV) antibody
- Systemic treatments in the two weeks preceding and during the study that may interact with any of the study drugs, such as: Glucocorticoids (po, im, iv), MAO inhibitors, Anti-depressants, Anti-seizure medications, Anti-psychotics, Antihistamines
- Subjects who require medications that inhibit the cytochrome P450 (CYP450) 2D6 pathway such as: Quinidine, Cimetidine, Type 1 antiarrhythmics, Phenothiazines, Selective serotonin reuptake inhibitors such as fluoxetine, paroxetine, and sertraline, reserpine, other anticholinergic drugs, and sympathomimetic drugs
- Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication
- Female subject who is pregnant or lactating
- Significant UV exposure in the four weeks before the study
- Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule
- Other unspecified reasons that, in the opinion of the Investigator or sponsor make the subject unsuitable for enrollment
- Subject is institutionalized because of legal or regulatory order
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
|
topical (mometasone furoate + nortriptyline HCl)
|
Experimental: 2
CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
|
topical (mometasone furoate + nortriptyline HCl)
|
Active Comparator: 3
0.1% mometasone furoate
|
topical mometasone furoate
|
Placebo Comparator: 6
Vehicle (placebo)
|
topical (placebo)
|
Active Comparator: 4
0.1% nortriptyline HCl
|
topical nortriptyline HCl
|
Active Comparator: 5
Karison® Creme (clobetasol-17-propinate 0.05%)
|
topical Karison® Creme (clobetasol-17-propinate 0.05%)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Full skin thinning produced by treatment of CRx-191 in comparison with its components at corresponding dose levels, and vehicle with a marketed corticosteriod. Assess tolerability and safety of CRx-191.
Time Frame: 28 Days
|
28 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Johannes Gassmueller, M.D., Bioskin GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
October 15, 2007
First Submitted That Met QC Criteria
October 15, 2007
First Posted (Estimate)
October 16, 2007
Study Record Updates
Last Update Posted (Estimate)
November 15, 2007
Last Update Submitted That Met QC Criteria
November 14, 2007
Last Verified
November 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Inflammatory Agents
- Dermatologic Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Anti-Allergic Agents
- Adrenergic Uptake Inhibitors
- Mometasone Furoate
- Nortriptyline
Other Study ID Numbers
- CRx-191-002
- EudraCT Number: 2006-005903-33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on CRx-191
-
Sonoma Orthopedic Products, Inc.TerminatedFracture of ClavicleUnited States
-
University of ChicagoNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Vienna Hospital AssociationRecruiting
-
University of ChicagoNational Institute on Aging (NIA)Enrolling by invitation
-
UniQure Biopharma B.V.Not yet recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoPatient-Centered Outcomes Research Institute; University of Chicago; Missing...Recruiting
-
QuiOSHL Medical; MidMichigan HealthUnknown
-
IRCCS Policlinico S. MatteoUnknownDiverticular Disease | Symptomatic Uncomplicated Diverticular DiseaseItaly
-
West German Center of Diabetes and Healthgbo Medizintechnik AGCompleted
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States